Table 3.
Published reports of the prognostic value of Ki-67 in multivariate analyses with Hazard ratio’s (HR) after adjument for covariates with prostate cancer-survival as end point.
| Reference | Cohort type | Cohort size | Cutoff (%) | p-value | HR (95% CI) | Covariates |
|---|---|---|---|---|---|---|
| Stattin et al (1997) | TURP, WW | 125 | 3 | 0.0023 | 2.51 (1.39–4.53) | G T A |
| Li et al (2004) | RX | 108 | 3.5 | 0.009 | 4.24 (1.43–12.57) | G T Tx |
| Pollack et al (2004) | RX | 496 | cont | 0.001 | 3.64 (2.15–6.16) | G T P Tx |
| Pollack et al (2004) | RX | 496 | 7.1 | 0.0174 | 2.07 (1.14–3.76) | G T P Tx |
| Berney et al (2009) | TURP, WW | 685 | 5 | 0.0003 | 1.83 (1.33–2.53) | G P Px |
| Khor et al (2009) | RX | 637 | 11.3 | 0.0007 | 2.35 (1.43–3.85) | G T A Tx |
| Fisher et al (2013) | BX, WW | 293 | 10 | 0.011 | 2.66 (1.36–5.2) | G P |
| Verhoven et al (2013) | BX RX | 468 | 6.2 | 0.0064 | 2.91 (1.35–6.26) | A G P T |
| Tollefson et al (2014) | BX | 451 | cont | 0.001 | 1.11 (1.07–1.15) | G Px |
| Tretiakova et al (2016) | RP | 1004 | cont | 0.02 | 1.10 (1.02–1.18) | G P Px |
| Tretiakova et al (2016) | RP | 1004 | 5 | ns | G P Px | |
| Lobo et al (2018) | BX | 189 | 5,33 | <0,05 | 1.91 (1.01–3.57) | A G T |
| Kammerer-Jacquet et al (this paper) | BX, WW | 756 | cont | 0.001 | 1.08 (1.06–1.10) | A E G P |
| Kammerer-Jacquet et al (this paper) | BX, WW | 756 | 5 | 0.007 | 1.93 (1.32–2.81) | A E G P |
Abbreviations: A = age; BX = needle biopsy; CI = confidence interval; CONT = continuous; E = extent; G = Gleason grade; ns = not significant; P = prostate-specific antigen; PCS = prostate cancer-specific survival; PCR = prostate cancer recurrence; Px = pathological features; RP = radical prostatectomy; RX = radiotherapy; T = clinical stage; Tx = treatment; TURP = transurethral resection of the prostate; WW = watchful waiting